MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-16-2026
Zomedica Corp. Current Ratio 2011-2026 | ZOM
Annual Current Ratio Zomedica Corp.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10.9 | 17.7 | 19.2 | 22.9 | 29.5 | 41.3 | 0.866 | 1.62 | 5.14 | 12.9 | 37 | 21 | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 41.3 | 0.866 | 18.3 |
Quarterly Current Ratio Zomedica Corp.
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 11.7 | 12.3 | 13.6 | 17.7 | 19 | 19.7 | - | 19.2 | 19.4 | 18 | 16.9 | 22.9 | 20.9 | 29.8 | 31.1 | 29.5 | 46.7 | 65.4 | 95.4 | 21.2 | 21.2 | 21.2 | 21.2 | 2 | 2 | 2 | 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 95.4 | 2 | 23.1 |
Current Ratio of other stocks in the Drug manufacturers industry
| Issuer | Current Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
2.34 | - | 7.5 % | $ 6.35 M |  USA |
 |
Aerie Pharmaceuticals
AERI
|
0.961 | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
0.386 | - | 10.11 % | $ 58.2 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
0.944 | - | 0.86 % | $ 117 M | USA |
 |
Organogenesis Holdings
ORGO
|
4.42 | $ 2.34 | -2.71 % | $ 308 M | USA |
 |
Pacira BioSciences
PCRX
|
2 | $ 25.24 | -0.67 % | $ 1.17 B | USA |
 |
DURECT Corporation
DRRX
|
1.95 | - | - | $ 50.1 M | USA |
 |
Cronos Group
CRON
|
6.63 | $ 2.59 | -2.27 % | $ 1.33 B |  Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
1.43 | $ 4.16 | -2.8 % | $ 58.5 M | USA |
 |
Catalent
CTLT
|
1.59 | - | - | $ 11.5 B | USA |
 |
Alimera Sciences
ALIM
|
1.43 | - | - | $ 142 M | USA |
 |
Athenex
ATNX
|
0.894 | - | -23.39 % | $ 1.76 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
2.35 | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
1.77 | - | - | $ 28.9 M |  Irlanda |
 |
Sonoma Pharmaceuticals
SNOA
|
1.48 | $ 1.06 | 1.44 % | $ 1.32 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
1.82 | - | - | $ 2.06 B |  France |
 |
Evoke Pharma
EVOK
|
0.733 | - | - | $ 36.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
9.82 | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
1.85 | - | 2.45 % | $ 38.1 M | Canada |
 |
Tilray
TLRY
|
4.41 | $ 6.09 | -7.16 % | $ 3.76 B | Canada |
 |
Bausch Health Companies
BHC
|
0.997 | $ 5.62 | -0.88 % | $ 2.05 B | Canada |
 |
Veru
VERU
|
2.15 | $ 2.26 | -1.31 % | $ 305 M | USA |
 |
Canopy Growth Corporation
CGC
|
2.13 | $ 1.1 | -4.35 % | $ 118 M | Canada |
 |
Jupiter Wellness
JUPW
|
6.86 | - | - | $ 33.6 M | USA |
 |
Viatris
VTRS
|
1.73 | $ 15.07 | 1.69 % | $ 18.1 B | USA |
 |
Harrow Health
HROW
|
1.15 | $ 39.41 | -2.64 % | $ 1.45 B | USA |
 |
Lannett Company
LCI
|
0.659 | - | 1.15 % | $ 7.11 M | USA |
 |
OrganiGram Holdings
OGI
|
4 | $ 1.38 | -1.43 % | $ 402 M | Canada |
 |
Evolus
EOLS
|
0.907 | $ 5.19 | -1.52 % | $ 335 M | USA |
 |
Sundial Growers
SNDL
|
5.69 | $ 1.34 | -8.8 % | $ 3.37 M | Canada |
 |
Emergent BioSolutions
EBS
|
1.55 | $ 8.12 | -1.34 % | $ 416 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
12.2 | - | - | $ 193 M | Canada |
 |
Radius Health
RDUS
|
0.418 | - | - | $ 1.42 B | USA |
 |
ProPhase Labs
PRPH
|
3.65 | - | - | $ 5.07 M | USA |
 |
cbdMD
YCBD
|
1.23 | $ 0.8 | -12.09 % | $ 3.45 M | USA |
 |
Assertio Holdings
ASRT
|
1.54 | $ 18.07 | 0.17 % | $ 116 M | USA |
 |
Solid Biosciences
SLDB
|
4.43 | $ 7.2 | -3.36 % | $ 630 M | USA |
 |
PetIQ
PETQ
|
2.4 | - | 1.64 % | $ 400 M | USA |
 |
Relmada Therapeutics
RLMD
|
12.5 | $ 7.31 | 0.97 % | $ 289 M | USA |
 |
Recro Pharma
REPH
|
1.62 | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
0.554 | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
6.12 | $ 0.95 | -3.63 % | $ 47.4 M | USA |
 |
PLx Pharma
PLXP
|
3.07 | - | -27.8 % | $ 2.56 M | USA |
 |
Aurora Cannabis
ACB
|
3.49 | $ 3.31 | -3.22 % | $ 86.3 M | Canada |
 |
Zynerba Pharmaceuticals
ZYNE
|
5.98 | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
2.83 | $ 0.9 | 0.66 % | $ 32.4 M | USA |
 |
Tricida
TCDA
|
1 | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
3.75 | $ 0.58 | -4.97 % | $ 2.49 M |  China |
 |
TherapeuticsMD
TXMD
|
3.49 | $ 2.1 | - | $ 24.3 M | USA |